Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn't a myth
While most biotech startups begin with a light bulb moment or in-licensed technology, Mythic Therapeutics’ roots trace back to a dining room table and an empty notebook.
Alex Nichols and Brian Fiske shared an office at Flagship before they left a few years ago to create something independent. They wanted to identify a meaningful problem for patients and solve it. Several notebooks later, they landed on a mission: creating a safer, more effective antibody-drug conjugate.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.